Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Brisbane, Camperdown, and Melbourne, AustraliaSee the 4 sites
- Phase
- Phase 2
Where in Australia
- Royal Brisbane and Women's HospitalBrisbane, AustraliaTaking people
- Royal Prince Alfred HospitalCamperdown, AustraliaTaking people
- St Vincent's HospitalMelbourne, AustraliaTaking people
- The Alfred HospitalMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06297226
- Record updated
- 6 October 2026
- Original description
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.Read full original descriptionShow less
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Inclusion: Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria; Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT); Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria; Participants must have measurable disease during screening; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion: Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded; Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis; Active or history of central nervous system involvement with MM; Other protocol-defined Inclusion/Exclusion criteria apply.